New study aims to predict hidden hepatitis b danger in transplant patients

NCT ID NCT07644026

Not yet recruiting Knowledge-focused Sponsor: Xiao Hui Zhang Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will develop and test a prediction tool (nomogram) to estimate the risk of hepatitis B virus reactivation in patients who have had a past infection and are undergoing a stem cell transplant. Researchers will follow 300 patients for at least 36 months after transplant, collecting data on reactivation events. No new treatments are being tested; the goal is to create a better way to identify high-risk patients so doctors can monitor them more closely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could give doctors a reliable way to predict which patients are at risk of hepatitis B reactivation after stem cell transplant, helping them take preventive steps.
What could go wrong: This is an observational study that only builds a prediction model, not a treatment. The model may not be accurate enough for all patients, and it won't directly prevent or cure the reactivation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HBV REACTIVATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HBV REACTIVATION HSCT

More trials for these conditions

Other studies related to the condition(s) this trial covers.